Skip to main content

Leprosy

3
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
2 programs
1
1
LEP-F1 + GLA-SEPhase 1/21 trial
LepVaxPhase 11 trial
Active Trials
NCT06627257Not Yet Recruiting54Est. Aug 2026
NCT03947437Unknown142Est. Apr 2025
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
MLCwAPhase 11 trial
Molecular Epidemiology of Leprosy - PhilippinesN/A1 trial
Active Trials
NCT00315809Completed310Est. Dec 2010
NCT01920750Completed10Est. Feb 1999
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Molecular Epidemiology of Leprosy - PhilippinesN/A
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
RifampinN/A1 trial
Active Trials
NCT06222372Recruiting1,100Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpLEP-F1 + GLA-SE
BiocorpLepVax
Allergy TherapeuticsMLCwA
Mission TherapeuticsRifampin
Allergy TherapeuticsMolecular Epidemiology of Leprosy - Philippines

Clinical Trials (5)

Total enrollment: 1,616 patients across 5 trials

NCT03947437BiocorpLEP-F1 + GLA-SE

Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

Start: Feb 2024Est. completion: Apr 2025142 patients
Phase 1/2Unknown
NCT06627257BiocorpLepVax

Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy

Start: Jan 2025Est. completion: Aug 202654 patients
Phase 1Not Yet Recruiting
NCT01920750Allergy TherapeuticsMLCwA

Leprosy Skin Test Antigens Phase 1

Start: Jan 1989Est. completion: Feb 199910 patients
Phase 1Completed
NCT06222372Mission TherapeuticsRifampin

Novel Interventions and Diagnostic Tests for Leprosy

Start: Mar 2020Est. completion: Dec 20261,100 patients
N/ARecruiting
NCT00315809Allergy TherapeuticsMolecular Epidemiology of Leprosy - Philippines

Molecular Epidemiology of Leprosy - Philippines

Start: Apr 2006Est. completion: Dec 2010310 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,616 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.